Beruflich Dokumente
Kultur Dokumente
8. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a 15. Van de Laar FA, Lucassen PL. No evidence for a reduction of myocar-
stronger predictor of cardiovascular events than fasting blood glucose in dial infarctions by acarbose. Eur Heart J 2004;25:1179; author reply
type 2 diabetes mellitus, particularly in women: lessons from the San 1179 –1180.
Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813– 16. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of
819. post-prandial hyperglycaemia in a large sample of patients with type 2
diabetes mellitus. Diabetologia 2006;49:846 – 854.
9. Sorkin JD, Muller DC, Fleg JL, et al. The relation of fasting and 2-h
postchallenge plasma glucose concentrations to mortality: data from the 17. Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national
Baltimore Longitudinal Study of Aging with a critical review of the sample of U.S. adults with type 2 diabetes. Diabetes Care 2001;24:
literature. Diabetes Care 2005;28:2626 –2632. 1734 –1738.
18. Monnier L, Lapinski H, Colette C. Contributions of fasting and post-
10. DECODE Study Group, the European Diabetes Epidemiology Group. prandial plasma glucose increments to the overall diurnal hyperglycemia
Glucose tolerance and cardiovascular mortality: comparison of fasting of type 2 diabetic patients: variations with increasing levels of HbA(1c).
and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397– 405. Diabetes Care 2003;26:881– 885.
11. Levitan EB, Song Y, Ford ES, et al. Is nondiabetic hyperglycemia a risk 19. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and post-
factor for cardiovascular disease? A meta-analysis of prospective stud- prandial glycemia on overall glycemic control in type 2 diabetes Impor-
ies. Arch Intern Med 2004;164:2147–2155. tance of postprandial glycemia to achieve target HbA1c levels. Diabetes
12. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Res Clin Pract 2007;77:280 –285.
Group. Acarbose treatment and the risk of cardiovascular disease and 20. UK Prospective Diabetes Study Group. Intensive blood-glucose control
hypertension in patients with impaired glucose tolerance: the STOP- with sulphonylureas or insulin compared with conventional treatment
NIDDM trial. JAMA 2003;290:486 – 494. and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet 1998;352:837– 853.
13. Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glu-
cosidase inhibition as monotherapy in elderly type 2 diabetic patients.
J Clin Endocrinol Metab 1998;83:1515–1522. Please see “Importance of Postprandial Glucose
14. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk Levels as a Target for Glycemic Control in Type 2
for myocardial infarction in type 2 diabetic patients: meta-analysis of
seven long- term studies. Eur Heart J 2004;25:10 –16.
Diabetes” on page 60 of this issue.